Gambia

Chronic hepatitis B is commonly the result of vertical transmission, and babies who are infected before they are one year old have a 90% risk of developing chronic hepatitis. Yet when administered within 24 hours of birth, the hepatitis B birth dose vaccine can prevent 75% to 95% of vertical transmission.With funding from Gavi, the Vaccine Alliance, PATH is employing a mixed methods approach to assess learning questions on the feasibility, acceptability, cost, market access, and impact of innovative strategies to improve the reach of timely hepatitis B birth dose vaccine for babies born in both in- and out-of-facility settings.By exploring innovative delivery strategies, assessing the role of community health systems, and understanding stakeholder perspectives, the project’s primary objective is to identify effective models for increasing hepatitis B birth dose coverage. Evidence and insights from this initiative will be applicable to countries planning for hepatitis B birth dose vaccine introduction as well as those seeking to deploy new strategies to increase coverage rates and timely administration within 24 hours of birth.

PATH is on the front lines of an effort to defeat meningitis by 2030.

Results from a Phase 2 clinical study of a pentavalent meningococcal meningitis vaccine designed for use in the African meningitis belt demonstrate the vaccine candidate to be safe, well-tolerated, and capable of producing strong immune responses to all five serogroups.

This brief summarizes the experience and capabilities of the PATH Cervical Cancer Team. For decades, PATH has been at the forefront of evidence-based strategies from HPV vaccine research and delivery to cervical cancer screening and treatment to ensure we best meet the needs and realities of these countries for the greatest health impact.

Access to screening and vaccination could significantly reduce HPV-related cancers in a generation. One country recently took an important step to protect their girls from HPV infection and cervical cancer.

This fact sheet provides an overview of the MVP Access Program, an initiative that grants researchers access to data sets and frozen serum samples collected during the MenAfriVac ® clinical studies in Africa. The fact sheet outlines MenAfriVac's ® development history, qualified uses of data, and how to request data and/or serum access.

PATH and its partners have been conducting clinical trials to evaluate a pneumococcal vaccine designed to meet needs in low-resource countries.

One mother’s story about enrolling her child in a vaccine trial.

Perspectives from The Gambia’s immunization program manager

Two clinicians reflect on evaluating early vaccines in The Gambia